Harvard Bioscience acquires CMA Microdialysis' preclinical business

Harvard Bioscience Inc., a global developer of tools for life science research and regenerative medicine, announced last month that it has acquired the preclinical business unit of CMA Microdialysis AB through a purchase of assets.
Register for free to listen to this article
Listen with Speechify
0:00
1:00
HOLLISTON, Mass.—Harvard Bioscience Inc., a global developerof tools for life science research and regenerative medicine, announced lastmonth that it has acquired the preclinical business unit of CMA MicrodialysisAB through a purchase of assets.
 
CMA Microdialysis AB is a privately held Swedishmanufacturer of microdialysis products. Founded in 1984, the company pioneeredthe microdialysis technique for in-vivosampling and monitoring of organs and tissues.
 
Harvard Bioscience says the acquisition is complementary toits Harvard Apparatus research products for neuroscience applications.
 
"The acquisition of CMA Microdialysis' preclinical businessprovides Harvard with a leading technology to add to our line of specializedtools for biological research," added Harvard Bioscience CEO Chane Graziano ina press release announcing the deal.
 
The business unit will remain in Sweden. Renamed DipylonMedical AB, the unit will have two business divisions: Eirus Medical, whichwill focus on the development of novel continuous blood glucose and lactatemonitoring systems based on smart catheter solutions, and ClinicalMicrodialysis, which will focus on the development, production and marketing oftissue monitoring solutions for in-vivomonitoring of injured organs.
 
Financial terms of the acquisition were not released.Harvard Bioscience says it expects the acquisition to be immediately accretiveto earnings.
 
Philip Siberg, CEO of CMA Microdialysis, stated that theacquisition has long-term strategic value for the company, as it creates valuefor its employees and customers.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue